Page 2 of 7
BI13.1-5 | Miscellaneous — Part 1
CLINICAL SCENARIO
Imagine you are observing a hospital ward round. The oncologist mentions that a patient's blood test shows a "rising CA-125" and orders a p53 mutation panel. In another bed, a patient with AIDS has dangerously low CD4 counts, and the biochemistry report flags abnormal lipid levels. Down the corridor, a man admitted for liver failure has a blood alcohol level that explains his jaundice. What connects these three patients? Biochemistry. Every diagnosis, every treatment decision, and increasingly every lab report processed by AI — all rest on the biochemical principles you'll learn in this module.
WHY THIS MATTERS
As a future doctor, you will encounter cancer, HIV/AIDS, and alcohol-related diseases almost daily. Understanding the biochemical basis behind these conditions will help you:
- Interpret tumor marker reports and advise patients about cancer screening
- Understand why antiretroviral drugs target specific enzymes in HIV
- Explain to a patient's family why chronic alcohol use damages the liver at a molecular level
- Appreciate how AI tools in the lab can catch errors and speed up diagnoses
This is not just theory — these concepts appear in clinical rounds, NEET PG, and real patient conversations.
RECALL
Before we dive in, let's recall what you already know from NCERT Biology (Class 12):
- DNA carries genetic information and can undergo mutations — changes in the nucleotide sequence
- Cells normally divide in a controlled way through mitosis, regulated by checkpoints
- Enzymes are proteins that catalyse specific biochemical reactions
- Viruses like HIV are obligate intracellular parasites that hijack host cell machinery
- The liver is the primary organ for metabolising drugs and toxins
These are your building blocks. We'll now see how disruptions in these normal processes lead to cancer, immune deficiency, and organ damage.
How Normal Cells Become Cancer Cells
Every cell in your body has a built-in "instruction manual" that tells it when to grow, when to stop, and when to self-destruct if something goes wrong. Cancer begins when these instructions are corrupted.
Figure: How Normal Cells Become Cancer Cells
Oncogenesis (from Greek oncos = mass, genesis = origin) is the process by which normal cells transform into cancer cells. Think of it like a car: normal genes are the accelerator and the brake. Cancer happens when the accelerator gets stuck AND the brake fails.
The "accelerators" are called proto-oncogenes — normal genes that promote cell growth and division. When a proto-oncogene is mutated, it becomes an oncogene — a permanently "ON" switch that drives uncontrolled cell division. Common examples include:
- RAS — mutated in ~30% of all human cancers; it's like a light switch stuck in the "on" position
- MYC — drives cell proliferation; amplified in many lymphomas and breast cancers
- HER2/neu — overexpressed in some breast cancers (this is why "HER2-positive" matters in treatment)
Oncogenes can be activated by:
1. Point mutations (a single letter change in DNA)
2. Gene amplification (too many copies of the gene)
3. Chromosomal translocation (a piece of one chromosome breaks off and joins another)
The Guardian of the Genome — p53 and Apoptosis
If oncogenes are the stuck accelerator, then tumour suppressor genes are the brakes. The most important of these is p53, often called the "guardian of the genome."
Figure: The Guardian of the Genome — p53 and Apoptosis
Here is what p53 does when it detects DNA damage in a cell:
- Cell cycle arrest — p53 pauses cell division so the damage can be repaired (like pulling over a car with a flat tyre before driving further)
- DNA repair activation — it recruits repair enzymes to fix the damage
- Apoptosis — if the damage is too severe to fix, p53 triggers apoptosis (from Greek apo = away, ptosis = falling), which is programmed cell death. Think of apoptosis as the cell's "self-destruct button" — it sacrifices itself to protect the whole body
When p53 itself is mutated (which happens in over 50% of human cancers), the cell loses its ability to stop dividing or self-destruct. Damaged cells keep multiplying, accumulating more mutations — this is how a tumour grows.
The balance between cell survival signals (from oncogenes) and cell death signals (from tumour suppressors like p53) determines whether a cell becomes cancerous. Two key protein families regulate apoptosis:
- Bcl-2 family — includes both pro-survival (Bcl-2, Bcl-xL) and pro-death (Bax, Bak) members
- Caspases — a cascade of enzymes that execute the cell death programme, like a chain of dominoes
CLINICAL PEARL
Clinical Pearl — The Li-Fraumeni Syndrome: Patients who inherit a mutated p53 gene from one parent develop cancers at a very young age — breast cancer, brain tumours, sarcomas, sometimes by their 20s. This rare syndrome dramatically illustrates why p53 is so critical. In the hospital, when you see a young patient with multiple different cancers, Li-Fraumeni syndrome should come to mind.
Biochemical Tumor Markers — Reading the Body's Signals
Tumour markers are substances — usually proteins — produced by cancer cells or by the body in response to cancer. They are measurable in blood, urine, or tissue and help doctors:
- Screen high-risk patients
- Diagnose specific cancers
- Monitor treatment response (if the marker drops, treatment is working)
- Detect recurrence after treatment
Here are the most clinically important markers you should know:
| Marker | Cancer Association | Sample | Clinical Use |
|---|---|---|---|
| AFP (Alpha-fetoprotein) | Liver cancer, testicular germ cell tumours | Blood | Screening + monitoring |
| CEA (Carcinoembryonic antigen) | Colorectal cancer | Blood | Monitoring recurrence |
| CA-125 | Ovarian cancer | Blood | Monitoring treatment |
| CA 19-9 | Pancreatic cancer | Blood | Monitoring |
| PSA (Prostate-specific antigen) | Prostate cancer | Blood | Screening + monitoring |
| HCG (Human chorionic gonadotropin) | Trophoblastic disease, testicular cancer | Blood/urine | Diagnosis + monitoring |
Important caveat: No tumour marker is 100% specific. PSA can be elevated in benign prostatic hyperplasia. CA-125 can rise in endometriosis. Markers are not standalone diagnostic tests — they are used alongside imaging and biopsy.
The biochemical basis of cancer therapy targets the very pathways we have discussed:
- Imatinib (Gleevec) blocks the BCR-ABL oncogene product in chronic myeloid leukaemia — it's like disconnecting the stuck accelerator
- Trastuzumab (Herceptin) targets HER2/neu in breast cancer
- Immune checkpoint inhibitors release the "brakes" on the immune system so it can attack cancer cells
- Antimetabolites (like 5-fluorouracil) mimic normal metabolites and block DNA synthesis in rapidly dividing cells
SELF-CHECK — Oncogenesis & Tumor Markers
A 45-year-old woman has a BRCA1 mutation. Her oncologist explains that a key tumour suppressor is also commonly mutated in her type of cancer. Which protein is known as the "guardian of the genome"?
A. RAS
B. MYC
C. p53
D. Bcl-2
Reveal Answer
Answer: C. p53
A patient with colorectal cancer undergoes surgery. Six months later, blood tests are ordered to check for recurrence. Which tumour marker is most appropriate?
A. AFP
B. PSA
C. CA-125
D. CEA
Reveal Answer
Answer: D. CEA